Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Mirati Therapeutics, Inc. (MRTX)

37.18   0.49 (1.34%) 03-31 16:00
Open: 36.8 Pre. Close: 36.69
High: 37.89 Low: 36.22
Volume: 1,176,109 Market Cap: 2,227(M)

Technical analysis

as of: 2023-03-31 4:20:35 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 50.1     One year: 54.95
Support: Support1: 36.16    Support2: 30.09
Resistance: Resistance1: 42.89    Resistance2: 47.04
Pivot: 39.68
Moving Average: MA(5): 37.13     MA(20): 40.01
MA(100): 51.94     MA(250): 61.42
MACD: MACD(12,26): -2.3     Signal(9): -2.1
Stochastic oscillator: %K(14,3): 10.2     %D(3): 8.7
RSI: RSI(14): 35.5
52-week: High: 101.3  Low: 32.95
Average Vol(K): 3-Month: 1,151 (K)  10-Days: 918 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MRTX ] has closed above bottom band by 23.6%. Bollinger Bands are 58.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 37.92 - 38.19 38.19 - 38.4
Low: 35.73 - 36.01 36.01 - 36.22
Close: 36.81 - 37.25 37.25 - 37.58

Company Description

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Headline News

Thu, 30 Mar 2023
Mirati (MRTX) Down 16.1% Since Last Earnings Report: Can It ... - Nasdaq

Tue, 28 Mar 2023
Is Mirati Therapeutics Inc (MRTX) a Leader in the Biotechnology Industry? - InvestorsObserver

Fri, 24 Mar 2023
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Purchased by ... - MarketBeat

Wed, 22 Mar 2023
Is Mirati Therapeutics Inc (MRTX) a Stock to Watch After Losing -7.71% This Week? - InvestorsObserver

Thu, 16 Mar 2023
Guru Fundamental Report for MRTX - Benjamin Graham - Nasdaq

Thu, 16 Mar 2023
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Given Consensus Rating ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 58 (M)
% Held by Insiders 4.32e+007 (%)
% Held by Institutions 1.5 (%)
Shares Short 9,880 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.4234e+008
EPS Est Next Qtl -0.86
EPS Est This Year -3.21
EPS Est Next Year -2.77
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -6
Return on Assets (ttm) 312.5
Return on Equity (ttm) -36.5
Qtrly Rev. Growth 1.18e+007
Gross Profit (p.s.) -92.41
Sales Per Share -66.7
EBITDA (p.s.) -3.6801e+008
Qtrly Earnings Growth -8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -580 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.56
Price to Cash Flow 1.37

Stock Dividends

Dividend 0
Forward Dividend 1.063e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.